JP2012529526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529526A5 JP2012529526A5 JP2012515088A JP2012515088A JP2012529526A5 JP 2012529526 A5 JP2012529526 A5 JP 2012529526A5 JP 2012515088 A JP2012515088 A JP 2012515088A JP 2012515088 A JP2012515088 A JP 2012515088A JP 2012529526 A5 JP2012529526 A5 JP 2012529526A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- adh2
- pharmaceutical composition
- ethanol
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 82
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 50
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 claims description 39
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 19
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 16
- 238000009825 accumulation Methods 0.000 claims description 12
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims description 10
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 230000029142 excretion Effects 0.000 claims description 4
- 238000011010 flushing procedure Methods 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 208000002173 dizziness Diseases 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 229960004285 fomepizole Drugs 0.000 claims 37
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 claims 32
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 230000015556 catabolic process Effects 0.000 claims 4
- 206010003591 Ataxia Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 206010033557 Palpitations Diseases 0.000 claims 2
- 206010000059 abdominal discomfort Diseases 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 208000022099 Alzheimer disease 2 Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 102000009645 Mitochondrial Aldehyde Dehydrogenase Human genes 0.000 description 5
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 230000008376 long-term health Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 208000024558 digestive system cancer Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- -1 hot flushes Chemical compound 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18588409P | 2009-06-10 | 2009-06-10 | |
| US61/185,884 | 2009-06-10 | ||
| PCT/US2010/037879 WO2010144518A1 (en) | 2009-06-10 | 2010-06-09 | Genotype specific methods for treating human subjects using 4- methylpyrazole |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015060341A Division JP2015155422A (ja) | 2009-06-10 | 2015-03-24 | ４−メチルピラゾールを使用してヒト対象を治療する遺伝子型特異的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012529526A JP2012529526A (ja) | 2012-11-22 |
| JP2012529526A5 true JP2012529526A5 (enExample) | 2013-03-14 |
| JP5836270B2 JP5836270B2 (ja) | 2015-12-24 |
Family
ID=43309203
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515088A Expired - Fee Related JP5836270B2 (ja) | 2009-06-10 | 2010-06-09 | ４−メチルピラゾールを使用してヒト対象を治療する遺伝子型特異的方法 |
| JP2015060341A Pending JP2015155422A (ja) | 2009-06-10 | 2015-03-24 | ４−メチルピラゾールを使用してヒト対象を治療する遺伝子型特異的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015060341A Pending JP2015155422A (ja) | 2009-06-10 | 2015-03-24 | ４−メチルピラゾールを使用してヒト対象を治療する遺伝子型特異的方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20120252857A1 (enExample) |
| EP (2) | EP2440049B1 (enExample) |
| JP (2) | JP5836270B2 (enExample) |
| KR (3) | KR20120032523A (enExample) |
| CN (2) | CN102458121A (enExample) |
| AU (1) | AU2010258821B2 (enExample) |
| DK (1) | DK2440049T3 (enExample) |
| ES (1) | ES2656489T3 (enExample) |
| NO (1) | NO2440049T3 (enExample) |
| PT (1) | PT2440049T (enExample) |
| SG (1) | SG176734A1 (enExample) |
| TW (1) | TWI523653B (enExample) |
| WO (1) | WO2010144518A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8901484B2 (en) * | 2012-04-27 | 2014-12-02 | Sanofi-Aventis Deutschland Gmbh | Quantification of impurities for release testing of peptide products |
| JP6421249B2 (ja) * | 2015-10-26 | 2018-11-07 | 株式会社日立製作所 | デバッグを支援する方法及び計算機システム |
| WO2019209123A1 (en) * | 2018-04-27 | 2019-10-31 | Remedius Biotech Limited | Diagnosis, risk reduction and treatment of conditions associated with elevated aldehyde levels |
| CN109381458B (zh) * | 2018-12-16 | 2020-09-01 | 李志武 | 甲吡唑及其盐在制备抗癫痫药物中的用途 |
| AU2023402122A1 (en) * | 2022-12-01 | 2025-06-12 | PICOENTECH Co., LTD. | Novel aldehyde dehydrogenase food and drug composition for improving behavior and motor function |
| WO2024117701A1 (en) * | 2022-12-01 | 2024-06-06 | PICOENTECH Co., LTD. | Food and drug composition containing novel aldehyde dehydrogenase for suppressing tremor or movement disorder |
| WO2024117698A1 (en) * | 2022-12-01 | 2024-06-06 | PICOENTECH Co., LTD. | Food and pharmaceutical composition for detoxifying endogenous aldehydes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106620A (en) | 1980-12-22 | 1982-07-02 | Takara Shuzo Co Ltd | Ameliorant for alcoholic metabolism |
| GB0404481D0 (en) | 2004-02-28 | 2004-03-31 | Rhodia Cons Spec Ltd | Soap control agent |
| US20080021083A1 (en) * | 2004-03-03 | 2008-01-24 | Daley Thomas E | 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance |
| US20090117079A1 (en) * | 2007-11-02 | 2009-05-07 | Monte Woodrow C | Methods and materials for treating or preventing diseases/disorders mediated by alcohol dehydrogenase |
-
2010
- 2010-06-09 EP EP10786733.5A patent/EP2440049B1/en not_active Not-in-force
- 2010-06-09 KR KR1020127000590A patent/KR20120032523A/ko not_active Ceased
- 2010-06-09 TW TW099118855A patent/TWI523653B/zh not_active IP Right Cessation
- 2010-06-09 AU AU2010258821A patent/AU2010258821B2/en not_active Ceased
- 2010-06-09 DK DK10786733.5T patent/DK2440049T3/en active
- 2010-06-09 JP JP2012515088A patent/JP5836270B2/ja not_active Expired - Fee Related
- 2010-06-09 KR KR1020147029368A patent/KR20140138318A/ko not_active Ceased
- 2010-06-09 KR KR1020167023761A patent/KR20160147709A/ko not_active Ceased
- 2010-06-09 PT PT107867335T patent/PT2440049T/pt unknown
- 2010-06-09 EP EP17206781.1A patent/EP3311811A1/en not_active Withdrawn
- 2010-06-09 CN CN2010800352852A patent/CN102458121A/zh active Pending
- 2010-06-09 ES ES10786733.5T patent/ES2656489T3/es active Active
- 2010-06-09 NO NO10786733A patent/NO2440049T3/no unknown
- 2010-06-09 WO PCT/US2010/037879 patent/WO2010144518A1/en not_active Ceased
- 2010-06-09 US US13/376,933 patent/US20120252857A1/en not_active Abandoned
- 2010-06-09 CN CN201710098759.1A patent/CN106943398A/zh active Pending
- 2010-06-09 SG SG2011090883A patent/SG176734A1/en unknown
-
2012
- 2012-06-21 US US13/529,695 patent/US20120322843A1/en not_active Abandoned
-
2015
- 2015-03-24 JP JP2015060341A patent/JP2015155422A/ja active Pending
-
2016
- 2016-09-20 US US15/270,842 patent/US20170007578A1/en not_active Abandoned
-
2017
- 2017-10-19 US US15/788,504 patent/US20180098964A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012529526A5 (enExample) | ||
| US8829058B2 (en) | Compounds and method for reducing uric acid | |
| JP5773870B2 (ja) | ヒドロキシ酪酸エステル及びその医学的使用 | |
| US10051880B2 (en) | Hydroxybutyrate ester and medical use thereof | |
| US20190151298A1 (en) | Methods and drug products for treating alzheimer's disease | |
| US8889724B2 (en) | Tetrazole compounds for reducing uric acid | |
| CN103298466B (zh) | 茶碱和非布索坦的联合治疗方法 | |
| CA2796268A1 (en) | Methods for treatment of sleep-related breathing disorders | |
| JP5836270B2 (ja) | ４−メチルピラゾールを使用してヒト対象を治療する遺伝子型特異的方法 | |
| HUE027050T2 (en) | Treatment of glomerulonephritis | |
| WO2012154770A1 (en) | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder | |
| JP2010501626A (ja) | 統合失調症を処置するためのビフェプルノックス用量 | |
| Cole | Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update | |
| JP6068447B2 (ja) | 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ | |
| JP5101306B2 (ja) | 糖尿病治療剤 | |
| JPH11116472A (ja) | 心不全の治療法 | |
| JP2008239500A (ja) | レプチン分泌促進剤 | |
| US8685952B2 (en) | Method for the treatment of diabetes | |
| JP2014513689A (ja) | 過活動膀胱の治療のためのトロスピウムと唾液分泌刺激剤の組合せ | |
| CN116983301A (zh) | 一种沙库巴曲缬沙坦钠药物组合物及其制备方法和用途 | |
| WO2020080398A1 (ja) | アルコール飲料摂取による悪酔い又は二日酔いの抑制剤 | |
| Xing et al. | Folic acid influences plasma homocysteine levels and arterial endothelial function in patients with unstable angina | |
| JP2019135048A (ja) | 飲料水の製造方法 | |
| HK1147446B (en) | Tetrazole compounds for reducing uric acid | |
| JP2009023977A (ja) | 血圧降下剤及び循環器疾患の治療薬 |